Abstract 6031: Impact of Pre-procedural C-reactive Protein on Intravascular Ultrasound Parameters following Everolimus-eluting Stent Implantation: Results from the SPIRIT III Trial
Background: It has been reported that pre-procedual C-reactive protein (CRP) correlates with neointimal hyperplasia following bare-metal stent as well as a certain type of drug-eluting stent implantation. The aim of this study was to investigate potential impact of inflammation, as assessed by high sensitivity-CRP (hs-CRP) collected pre-procedure, on neointimal hyperplasia following everolimus-eluting stent (EES) implantation.
Methods: Data were obtained from the SPIRIT III trial, a randomized controlled trial comparing an EES with a paclitaxel-eluting stent. Enrolled patients fulfilled the following criteria
patients treated with EES
stable angina; and
volumetric intravascular ultrasound (IVUS) analysis available at 8 months follow-up.
Volume index (volume/length) was calculated for vessel (VVI), plaque (PVI), neointima (NIV), and lumen (LVI). Percent neointimal volume (%NIV) was calculated as (NIV/SVI)× 100. Cross-sectional narrowing (CSN) was defined as neointimal area divided by stent area (%).
Results: One-hundred thirty two patients met the inclusion criteria (mean age; 65±9 years, male; 75%). There was no significant correlation between hs-CRP and VVI, PVI, and LVI at either baseline or 8 months follow-up. Furthermore, hs-CRP did not correlate with %NIV (r=−0.071, P=0.416) and max CSN (r=−0.020, P=0.819) at follow-up (figure⇓).
Conclusion: Pre-procedual inflammation assessed by hs-CRP did not affect the neointimal hyperplasia at 8 months following everolimus-eluting stent implantation.